Influenza virus infection frequently causes severe acute respiratory infection and is sometimes accompanied by fever, muscle pain, pneumonia, otitis media, meningitis and encephalitis [1, 2] . These clinical symptoms often become severe, especially in high-risk groups such as the elderly and infants [3, 4] . Treatment with anti-influenza virus agents plays an important role in influenza virus control. Amantadine and its analogue, rimantadine, act as viral M2 channel blockers, and zanamivir and oseltamivir are viral neuraminidase (NA) inhibitors, and have been used for the treatment and prevention of influenza virus infection [5] [6] [7] . However, amantadine-resistant viruses have begun to appear at a high rate clinically, and the appearance of resistant viruses has also been reported in treatment with NA inhibitors [8] [9] [10] . Therefore, new or alternative antiinfluenza virus agents that are effective against resistant viruses need to be developed.
Sasa albo-marginata is well known as Kumazasa in Japan. Extracts of Kumazasa have been used as traditional medicine and as wrapping materials for foods throughout Asia. The water-soluble fraction of this plant has a number of biological activities, including antiulcerogenic and anti-inflammatory properties [11] [12] [13] . With the development of drug resistance, which is a constant concern, the search for new antiviral agents from a variety of sources, including plants, has assumed more urgency than in the past [14] . A recent study in Introduction our laboratory revealed that tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone), which is derived from the hot water extract of Sasa albo-marginata (Figure 1 ), has anti-human cytomegalovirus activity [15] . In the present study, we show that tricin has anti-influenza virus properties in vitro and in vivo.
Methods

Cells and viruses
Madin-Darby canine kidney (MDCK) cells were purchased from the American Type Culture Collection, and MDCK cells were grown and maintained in Eagle's minimum essential medium (EMEM; Nissui Pharmaceutical Co. Ltd, Tokyo, Japan) supplemented with 5% fetal calf serum (Bocknek Ltd, Rexdale, ON, Canada), L-glutamine (0.3 mg/ml; Nacalai Tesque, Inc., Kyoto, Japan), streptomycin (100 µg/ml; Nacalai Tesque, Inc.) and penicillin (100 units/ml; Nacalai Tesque, Inc.). For the influenza virus infection medium, EMEM supplemented with 0.4% bovine serum albumin (BSA; Cohn Fraction V, pH 7.0; Wako Pure Chemical Industries, Ltd, Osaka, Japan), L-glutamine (0.15 mg/ ml; Nacalai Tesque Inc.), vitamin solution (MEM Vitamin Solution 100X, GIBCO, Grand Island, NY, USA), streptomycin (50 µg/ml; Nacalai Tesque, Inc.) and penicillin (50 units/ml; Nacalai Tesque, Inc. 
Compound
Tricin, 4′,5,7-trihydroxy-3′,5′-dimethoxyflavone ( Figure 1 ) was synthesized and suspended in dimethyl sulfoxide (DMSO). We prepared tricin through a condensation reaction of methyl benzoate (1) with acetophenone (2), followed by acid cyclodehydration. The required methyl 4-O-tert-butyldimethylsilyl-3,5-dimethoxybenzoate (1) and 2′,4′-O-bis (tert-butyldimethylsilyl) -6′-hydroxyacetophenone (2) were prepared by protection of suitable starting materials with tert-butyldimethylsilyl chloride in tetrahydrofuran in the presence of N,N-diisopropylethylamine. The condensation reaction of 1 with 8 equivalents of lithium bis (trimethylsilyl) amide (LiHMDS) and 1.5 equivalents of 2 in tetrahydrofuran at -78°C raised to room temperature over 3 days gave intermediate 3 as a mixture of tautomers. These were subjected to acid cyclodehydration and deprotection with 0.5% H 2 SO 4 in acetic acid at 100°C overnight. These reaction conditions afforded the corresponding tricin 4 at an overall yield of 68%. The purity of the tricin was checked using reversephase high-performance liquid chromatography and confirmed to be 99%.
Amantadine hydrochloride was purchased from Wako Pure Chemical Industries, Ltd, and dissolved in 
Analysis of gene expression
Confluent monolayers of MDCK cells in 6-well plates (Falcon number 3046; Becton Dickinson) were infected with the influenza A/Solomon islands/3/2006 (H1N1) virus, at an MOI of 1.0. At 1 h after infection, the inoculum was removed, and cells were treated in 2 ml of DMEM with or without the indicated concentrations of tricin. RNA samples were collected at 4 and 5 h post-infection. Total RNA was extracted from mock-or virusinfected cells treated with or without tricin using the chaotropic Trizol method, followed by Isogenchloroform extraction and isopropanol precipitation [20] . Prior to the reverse transcriptase (RT) reaction, potentially contaminating residual genomic DNA was eliminated with DNase I (Takara Shuzo, Otsu, Japan). [21] [22] [23] ; and β-actin primers (forward: 5′-ATC ATG TTT GAG ACC TTC AAC-3′, reverse: 5′-CAG GAA GGA AGG CTG GAA GAG-3′) [14] . Results were normalized against β-actin RNA levels.
Haemagglutination inhibition assay
Haemagglutination inhibition assay was carried out as described by Suzuki et al. [24] . Briefly, virus suspension (4 HA units/20 µl) was incubated for 1 h at 4°C with a twofold serial dilution of 190 µM tricin (20 µl) with 0.01% gelatin-containing phosphate-buffered saline (PBS), in 96-well microtitre plates (Falcon number 3077, Becton Dickinson). After adding 0.5% (v/v) of chicken erythrocytes to each well, the plates were kept for 1 h at 4°C.
Neuraminidase inhibition assay
NA inhibition assay was carried out using an NA-Star™ influenza NA inhibitor resistance detection kit (Applied Biosystems, Foster City, CA, USA). The assay was performed according to the manufacturer's protocol using an LB940 plate reader (Berthold Technologies GmbH & Co.KG, Bad Wildbad, Germany). The influenza A/Solomon islands/3/2006 virus culture supernatant (cultured on MDCK cells) was initially serially diluted in phenol red-free EMEM to provide an appropriate NA titre to the assay (signal-to-noise ratio of 40:1). Final drug concentrations ranged from 0.0009 to 10 µM for tricin and from 0.03 to 320 nM for oseltamivir carboxylate.
Influenza virus infection in mice
Tricin suspended in 5% Arabic gum was examined in an intranasal influenza virus infection model in mice. DBA/2 Cr mice were intranasally infected or mock-infected with a mouse-adapted influenza A/PR/8/34 virus at 1,600 plaque forming units/25 µl or PBS, respectively, under anaesthesia [19, 25] . Tricin suspension (20 or 100 µg/kg) of 0.2 ml was orally administered to the mice by gavage, once at 4 h prior to and twice after virus infection on day 0, and three times daily to day 5 after infection. A 5% Arabic gum solution was used for the control and mockinfected mice. Six mice from each group were weighed daily from day 0 to day 8 after infection, and the changes were calculated based on the body weight of each mouse on day 0. The number of surviving mice in a group was observed daily from day 0 to day 14.
Statistical analysis
Statistically significant differences between tricintreated and untreated groups were evaluated using Tukey's test. Based on net body weight change data, the differences between the treated and untreated groups were analysed using repeated measures twoway ANOVA from day 0 to day 8 after infection. In the next experiment, the virucidal effect of tricin was examined. Cell-free influenza A/Solomon islands/3/2006 (H1N1) virus was incubated with 30 µM tricin for 1 to 8 h. However, the infectivity of cell-free viruses was unchanged ( Figure 3A) . The cytotoxic effects of tricin were then examined after incubation (1, 24 and 72 h) of MDCK cells with concentrations of 0.37-30 µM tricin. However, no cytotoxic effects were observed, even at the highest tricin concentration ( Figure 3B ).
Results
In vitro anti-influenza virus activity of tricin
Effect of tricin on influenza virus protein synthesis
To determine the molecular nature of influenza HA and M proteins expressed in the tricin-treated cells (3.3, 10 and 30 µM), we examined their synthesis in MDCK cells at the indicated time intervals by western blot analysis. As shown in Figure 4 , influenza HA and M proteins were synthesized in virus-infected, tricinuntreated cells at 5 and 8 h post infection. By contrast, HA protein synthesis was strongly reduced by treatment of the influenza-virus-infected cells with tricin at 5 and 8 h post infection ( Figure 4; lanes 2, 3 and 4) . Moreover, the M protein synthesis was also inhibited by tricin treatment (Figure 4; lanes 7, 8 and 9) . 
Effect of tricin on the biological activities of influenza A virus
To investigate whether the effects of tricin on plaque inhibition are directly due to the biological activities in the virus replication cycle of influenza A viruses, we carried out HA inhibition and NA inhibition activity assays. First, we examined the effect of tricin on haemagglutination. Figure 6A ). The tricin-untreated control, however, demonstrated a reduction in haemagglutination. These results suggest that tricin does not interfere with viral attachment to host cell surfaces. Next, we examined NA inhibitor activity of tricin against influenza A/Solomon islands/3/2006 (H1N1) virus using an NA-Star™ influenza NA inhibitor resistance detection kit. When serially diluted agents (oseltamivir carboxylate, DMSO and tricin) were incubated with the virus, the values of light signal intensity were completely inhibited at >32 nM oseltamivir carboxylate, which was the positive control ( Figure 6B ). However, the light intensity values following treatment with tricin were unchanged, even at the highest concentration of tricin, and similar to those of the negative control (treatment with NA-Star assay buffer or DMSO; Figure 5B ). Thus, tricin was found to exhibit a potential anti-influenza virus efficacy without NA inhibition. These results indicated that the tricin does not affect the biological activities of influenza A viruses, including HA and NA activities.
Anti-influenza virus efficacy of tricin in vivo
Tricin efficacy was examined in a murine influenza virus infection model. In this model, weight changes of infected mice are a useful indicator of the morbidity of mice after a challenge with influenza virus [26, 27] . We used 20 and 100 µg/kg of tricin as the doses for mice. Efficacies of the two doses were assessed by weight changes of the infected mice from day 0 to day 8 after infection. As shown in Figure 7A , the mean body weight of the infected mice administered 5% Arabic gum solution (control) decreased markedly from day 0 to day 8 after infection compared with that in the mock-infected mice. The administration of tricin significantly reduced the loss of mean body weight in the infected mice from day 0 to day 8 after infection (20 µg/kg, P=0.05; 100 µg/kg, P=0.03). Single oral administration of 2,000 mg/kg tricin did not produce body weight loss in the uninfected mice (MK et al., data not shown). Thus, tricin was found to exhibit potential anti-influenza virus efficacy in mice without toxicity.
To confirm the potential anti-influenza virus efficacy of tricin, we examined the dose-dependent efficacy of tricin on the survival rate of the infected mice ( Figure 7B ). The infected mice were orally administered tricin at 20 and 100 µg/kg. Five infected mice that received 5% Arabic gum solution (control) died by day 14 after infection. However, 67% and 83% of the infected mice that received tricin at 20 and 100 µg/kg, respectively, were still alive on day 14 after infection. Thus, tricin was effective against flu virus infection in a dose-dependent manner and its anti-influenza virus efficacy in mice was confirmed.
Discussion
In this study, we found that tricin exhibited antiinfluenza virus activity in vitro and in vivo. This is the first study demonstrating the anti-influenza virus activity of tricin. Tricin inhibits influenza virus production in a dose-dependent manner at doses of 3. (Table 1) . Moreover, viral replication of this novel influenza A virus was >95% inhibited by 30 µM tricin treatment (Figure 2A ). This novel influenza A virus was also resistant to amantadine. Therefore, the anti-influenza virus mechanisms of tricin may differ from those of amantadine. Amantadine and its analogue, rimantadine, act as viral M2 channel blockers, and zanamivir and oseltamivir are viral sialidase inhibitors [5] [6] [7] . Amantadine and rimantadine are active against influenza A virus only, and produce rapid drug-resistant variants. Studies on the mechanisms of action are consistent with tricin mainly affecting the early processes of the viral replication cycle. The first step of the influenza virus replication cycle involves the binding of viral HA to sialic acid receptors on the host cell surface. Erythrocyte haemagglutination is mediated by the interaction of viral HA and sialic acid containing glycoconjugates on the surfaces of erythrocytes [28] [29] [30] . However, tricin had no inhibitory effect on haemagglutination and NA activity ( Figure 6A and 6B). These results suggest that the decrease in progeny virus production is not due to the inhibition of viral HA and NA. Tricin was added to before or after virus-infected cells at various times; we found that tricin inhibited viral replication both before and after viral adsorption to the host cell (KY et al., data not shown). The data suggests that tricin might act at the early to middle stage of the viral replication cycle, presumably via blockage of viral protein production by host-mediated molecules. Indeed, we found that tricin may act as an immunomodulator (TM et al., unpublished observations). Tricin has been reported to have a chemical composition and pharmacological activity of an anti-human cytomegalovirus agent [15] . We also found that prostaglandin E2 accumulation and induction of cyclooxygenase-2 (COX-2) protein synthesis by human cytomegalovirus infection were inhibited by tricin treatment [31] . Therefore, tricin may also be a novel COX synthesis inhibitor. Lee et al. [32] and Li et al. [33] reported that influenza A virus has been shown to induce COX-2 accumulation. Furthermore, COX inhibitors substantially block influenza A virusinduced inflammatory responses. Although the effects of COX inhibitors on influenza disease in humans have not yet been tested, there are indications that this class of drugs will help control herpes simplex virus and influenza virus in an animal model; COX-2 inhibitors have been shown to suppress herpes simplex virus reactivation in a mouse model of latency [34] and exhibit anti-influenza virus activity in mice [35] .
Tricin administered orally significantly reduced body weight loss of infected mice ( Figure 7A ) and prolonged survival times ( Figure 7B ). The dose of 20 µg/ kg of tricin was effective in countering body weight loss and prolonging the survival time of infected mice, indicating that the efficacy of tricin against influenza virus was dose-dependent. In the in vitro study, tricin did not show cytotoxicity against MDCK cells ( Figure  3B) , and similar to results of the in vivo study, no body weight loss was observed in mice administered tricin at 2,000 mg/kg. Thus, tricin is likely adsorbed from the alimentary tract in mice thereby exhibiting anti-influenza virus action.
In conclusion, our results predict that tricin might be candidates as natural anti-influenza virus compounds and useful as therapeutic agents in influenza-virus-infected hosts. Further investigation into the mechanisms of its antiviral action, as well as the chemical modification of tricin, should be conducted to further develop these compounds for clinical use.
